Hims & Hers Health Inc Dossier
|
SectorHealth Care IndustryDrug Manufacturers - Specialty & Generic Beta (adjusted)1.94 Intrinsic Value $12.61median of 3 methodsbased on filings through 30 Jun 2026 Market Price $29.30Price as of 1 Oct 2026 Significantly overvaluedIntrinsic value is 57% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% marker beyond scale (-57%) Data confidence Sign in to view data confidence Market Cap $6.8B Enterprise Value $7.6B Shares Outstanding 236.4M diluted Moat Rating None Next Earnings Date2 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Hims & Hers offers a compelling long-term growth platform but a balanced stance is appropriate at this research cut-off. Second-quarter revenue increased 38% year over year, subscribers reached 2.891 million, and management raised 2026 revenue guidance. The completed Eucalyptus acquisition materially expands the international opportunity. Offsetting those strengths, second-quarter gross margin declined to 64% from 76%, the company reported a net loss and negative quarterly free cash flow, and international expansion adds integration and regulatory complexity. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$23.00 Mean target$31.15 High · most bullish analyst$42.00 Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $23.0024% Revenue falls below guidance, gross-margin pressure persists, or regulatory and integration challenges limit the benefits of international expansion. Continued losses, legal contingencies, or weaker subscriber economics would reduce confidence in the 2030 objectives. Base CaseCentral scenario $31.1555% Matches the consensus meanThe company delivers within its 2026 revenue and adjusted EBITDA guidance ranges while integrating Eucalyptus and rebuilding margin from the second-quarter level. Growth remains strong but is balanced by lower gross margin, acquisition execution requirements, healthcare regulation, and near-term GAAP losses. Bull CaseUpside scenario $42.0021% Domestic growth continues to accelerate, international operations scale successfully following the Eucalyptus acquisition, and technology-led efficiencies improve profitability. Progress toward management's 2030 targets of at least USD 6.5 billion in revenue and USD 1.3 billion in adjusted EBITDA would strengthen the long-term case. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |